Hyperbaric Oxygen Therapy: Supporting Healing at the Cellular Level

Hyperbaric oxygen therapy (HBOT) does far more than help stubborn wounds heal; it can support cellular metabolism, calm inflammation, and promote repair in the brain and body when people feel “stuck” in chronic symptoms. This article explains how HBOT works, how soft and hard chambers differ, and when mild HBOT with an oxygen concentrator may make sense as part of a comprehensive plan.

Most people think of Hyperbaric Oxygen Therapy as something reserved for hospitals, used for wound care, diabetic ulcers, or acute injuries like carbon monoxide poisoning. That is true—but it only scratches the surface of what this therapy can do.

In clinical practice, we often see patients who are not acutely injured but whose bodies are not healing the way they should. They feel stuck. Fatigued. Foggy. Inflamed. Their labs may not fully explain it, but their symptoms are real and disruptive to daily life. In many of these cases, one of the missing pieces is efficient oxygen delivery and utilization at the cellular level.

Why Oxygen Delivery Matters

Healing is not just about structure; it is about function. Every cell in your body depends on oxygen to produce energy inside the mitochondria, the “power plants” of the cell that generate ATP, your body’s usable energy currency. When tissues are inflamed, toxic, infected, or under chronic stress, oxygen delivery and use can become less efficient, even when standard blood flow studies look “normal.”

When cells are not getting or using oxygen well, it can create a cascade:

• reduced cellular energy (ATP) production
• increased oxidative stress and inflammation
• slower tissue repair and regeneration
• ongoing neurologic and metabolic symptoms such as fatigue, brain fog, and pain

This pattern is particularly relevant in patients experiencing:

• brain fog or cognitive slowing
• chronic fatigue or post‑viral fatigue
• post‑concussion symptoms
• mold‑related or mycotoxin‑related illness
• chronic inflammatory or autoimmune conditions

In these situations, the issue is not always permanent damage—it is often dysfunction in how cells handle oxygen, energy production, and inflammation. Hyperbaric Oxygen Therapy helps restore that function.

How Hyperbaric Oxygen Therapy Works

Hyperbaric Oxygen Therapy (HBOT) involves breathing oxygen in a pressurized chamber. Under increased pressure, oxygen does not just ride on red blood cells; it also dissolves directly into the blood plasma at much higher levels, allowing it to reach tissues that may have compromised microcirculation or edema.

There are two main ways this is done:

• Hard chambers (hospital‑style metal chambers) that can go to higher pressures (often 2.02.4 atmospheres absolute, ATA) and typically deliver 100% oxygen for serious, acute, or limb‑threatening conditions.
• Soft or “mild” chambers (flexible, portable chambers) that usually operate at lower pressures around 1.31.5 ATA and are often used in outpatient or wellness settings, with room air or an oxygen concentrator.

This pressure‑plus‑oxygen combination creates several important physiologic effects:

1. Increased oxygen availability at the cellular level
   Higher dissolved oxygen means more fuel for mitochondria to make ATP in tissues that are struggling, including the brain, muscles, and injured tissues.
2. Cellular signaling and gene expression changes
   HBOT is not just a “super oxygen” treatment; it acts like a controlled oxidative stress signal that turns on and off specific genes related to inflammation, antioxidant defenses, and repair.

Research shows that HBOT can:

• reduce pro‑inflammatory cytokines such as IL‑6 and others involved in inflammatory states
• increase regulatory T cells (Tregs), which help calm immune overactivation and restore immune balance
• activate antioxidant pathways, including Nrf2, which upregulates the body’s own antioxidant and detoxification enzymes
• support stem cell mobilization and signaling involved in tissue repair and regeneration

These changes influence how the body regulates inflammation, protects mitochondria, and repairs damaged or dysfunctional tissues over time.

HBOT and the Brain

The brain is extremely sensitive to both oxygen levels and inflammation. Studies in patients with mild traumatic brain injury and persistent post‑concussion symptoms show that HBOT can improve blood flow, oxygen metabolism, and multiple domains of cognitive function, including attention, processing speed, memory, and executive function. Imaging studies have also documented increased activity and improved connectivity in specific brain regions after HBOT, correlating with symptom improvements.

Because of this, HBOT is increasingly considered in conditions where brain function and energy production are impaired, such as:

• post‑concussion syndrome
• traumatic brain injury (mild to moderate)
• post‑infectious cognitive changes, including some cases of long COVID and chronic fatigue syndromes

Patients often describe clearer thinking, better word‑finding, improved focus, and more mental stamina after a series of treatments, which aligns with findings from clinical trials.

HBOT and the Autistic Brain: Addressing the Physiology, Not Just the Behavior

For families navigating autism spectrum disorders, conventional care often focuses on behavior — what a child can or cannot do, and how to manage it. But a growing body of research points to measurable physiologic patterns underlying many of those challenges: cerebral hypoperfusion, neuroinflammation and elevated inflammatory cytokines (including TNF‑α and NF‑κB), increased oxidative stress, mitochondrial dysfunction, and immune dysregulation. These are not abstract findings; they correlate directly with the communication, social awareness, and sensory symptoms families observe every day.

HBOT directly addresses many of these mechanisms by improving tissue oxygenation and modulating inflammation and oxidative stress. In a multicenter randomized, double‑blind controlled trial, children with autism receiving HBOT at 1.3 ATA and 24% oxygen for 40 hourly sessions showed significant improvements in overall functioning, receptive language, social interaction, eye contact, and sensory/cognitive awareness compared to controls. When cerebral blood flow improves and neuroinflammation and oxidative stress decrease, the brain is better able to regulate, connect, and communicate.

Beyond behavior rating scales, imaging and physiologic data support these changes. Several reports have documented increased regional cerebral perfusion in temporal, frontal, and other cortical regions after courses of hyperbaric oxygen therapy in individuals with autism, alongside reductions in core autism symptoms. While not every child responds, these studies suggest that targeting perfusion and inflammation can positively influence real‑world communication, attention, and sensory processing.

Why Antioxidant Preparation Matters

Children on the autism spectrum frequently present with already‑depleted antioxidant reserves — particularly glutathione, the body’s primary intracellular antioxidant and a key detoxification molecule. Multiple studies have shown lower total and reduced glutathione and a more oxidized glutathione redox ratio in autism, indicating increased oxidative stress and reduced antioxidant capacity in both peripheral tissues and the brain. In practical terms, this means many autistic children are starting from a physiologic baseline that is more vulnerable to oxidative and inflammatory insults.

HBOT works in part by creating a controlled, temporary increase in oxygen tension and reactive oxygen species, which then stimulates adaptive antioxidant, mitochondrial, and perfusion responses. In a system that is already depleted, this acute oxidative signal can be harder to tolerate if antioxidant reserves and detoxification pathways are not supported first. This is why we prioritize assessing and supporting antioxidant capacity — glutathione production, redox balance, and detoxification pathways — before initiating treatment.

When these foundations are in place, HBOT is often both more effective and better tolerated, allowing the therapy to shift physiology toward better perfusion, lower inflammation, and improved neuronal function rather than simply adding another stressor. For families who have been searching for answers, that preparation is not a delay; it is the difference between a good outcome and a great one.

Inflammation, Immunity, and Mitochondria

A key reason HBOT can help “stuck” patients is its impact on inflammation and mitochondrial function.

Modulating the Immune Response

In chronic inflammatory and autoimmune conditions, the immune system can be stuck in an overactive, self‑perpetuating loop. Experimental and clinical data suggest that HBOT helps shift the balance between inflammatory Th17 cells and anti‑inflammatory regulatory T cells (Tregs), reducing the Th17/Treg ratio and promoting a more tolerant, less inflamed immune environment. This shift has been observed in models of autoimmune arthritis, diabetes, and transplant tolerance.

By lowering pro‑inflammatory cytokines and supporting Treg expansion, HBOT may help reduce:

• joint and soft tissue inflammation
• neuroinflammation contributing to brain fog and mood symptoms
• chronic inflammatory pain states

Protecting and Supporting Mitochondria

Mitochondria are both the engines and sensors of cellular stress. HBOT has been shown to influence mitochondrial function, helping to improve ATP production while also upregulating antioxidant systems that protect mitochondria from oxidative damage. Controlled intermittent “oxygen spikes” appear to trigger adaptive responses, making cells more resilient to future stress in a process sometimes called hyperoxichypoxic paradox preconditioning.

This is particularly relevant for patients with:

• chronic fatigue and post‑exertional malaise
• myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS)
• fibromyalgia and central sensitivity syndromes

Evidence is still emerging and somewhat mixed, but several small studies and case series have shown improvements in fatigue, pain, sleep, and cognitive symptoms in fibromyalgia and ME/CFS patients after HBOT, with some demonstrating changes in brain connectivity on imaging.

When the Inflammatory Signal Won’t Turn Off: HBOT and Residual Spike Protein

Some patients arrive having done a great deal of things right: cleaner diet, reduced toxic load, supported detoxification pathways — and yet they remain stuck. Fatigued. Foggy. Inflamed in ways standard testing does not fully explain.

For a growing number of these patients, one piece of the puzzle is residual spike protein from SARS‑CoV‑2. Research shows that spike protein-mediated effects on blood vessels and the immune system can persist beyond the initial infection and contribute to post‑acute COVID symptoms. Persistent spike‑driven signaling is linked to endothelial dysfunction, microcirculatory impairment, and ongoing inflammatory cytokine activity, even when routine labs appear “normal.” The result is tissue that is alive but not thriving, mitochondria that cannot produce energy efficiently, and cells starved of what they need to repair and restore.

HBOT addresses this pattern through three converging mechanisms. First, by dissolving oxygen directly into the plasma — not just loading red blood cells — HBOT can deliver oxygen to tissues with impaired microcirculation that cannot be adequately supported through normal pathways. Second, HBOT supports mitochondrial biogenesis and function, helping stimulate the creation of new mitochondria and improving the efficiency of existing ones. Third, it modulates redox and inflammatory signaling, with studies suggesting reduced inflammatory cytokine release, protection of the endothelium, and a shift away from chronic, maladaptive immune activation. For those who feel they have been doing everything right and still cannot break through, this kind of targeted support for microcirculation, mitochondria, and redox balance may represent the missing physiologic piece.

Soft vs. Hard Chambers: Safety and Practical Use

Most people picture the large metal hospital chambers when they think of HBOT. Those hard chambers are designed to deliver higher pressures with 100% oxygen and are essential for conditions like serious wounds, radiation injury, decompression sickness, and certain infections. They are powerful tools, but they require strict medical supervision and carry higher risks of oxygen toxicity and pressure‑related ear or sinus injury at the higher settings used in hospitals.

Soft chambers (often called mild hyperbaric chambers) are different. They are portable, usually made of a flexible material, and typically pressurize to milder levels around 1.31.5 ATA. At these lower pressures, the risk of barotrauma (pressure‑related injuries) and oxygen toxicity is significantly lower than in higher‑pressure, 100% oxygen hospital protocols, which is one reason they are often used in outpatient or home‑based wellness settings under professional guidance.

Why a Soft Chamber Is Still More Than “Just Air”

Even breathing room air inside a soft chamber at 1.3 ATA produces measurable changes in oxygen delivery; physiologic modeling and clinical reports suggest tissue oxygen tension can increase by 50% or more compared with normal room conditions at 1.0 ATA. When paired with an oxygen concentrator delivering oxygen‑enriched air, dissolved oxygen levels in the plasma rise further, allowing oxygen to reach tissues with subtle microcirculatory problems that may not be adequately supported through red blood cells alone.

At these lower pressures, the risk of oxygen toxicity and barotrauma is significantly lower than with higher‑pressure, hospital‑grade hard chamber protocols, which is why soft chambers are often used as a gentler entry point for patients dealing with chronic functional issues rather than acute emergencies. They do not replace hard chambers for indications such as serious wounds, radiation injury, or life‑threatening infections, where higher pressures and tightly controlled medical protocols are required, but for the kinds of patients we most often see, soft chambers can offer a clinically meaningful and generally well‑tolerated path forward.

Hyperbaric Oxygen Therapy is often considered for patients dealing with:

• post‑concussion syndrome and brain injury recovery
• brain fog and cognitive dysfunction, including some long COVID and chronic inflammatory states
• chronic fatigue patterns, ME/CFS, and fibromyalgia (in carefully selected cases)
• mold and mycotoxin‑related illness, where inflammation, microcirculation, and mitochondrial stress overlap
• joint inflammation and soft tissue recovery after injuries or surgery

In many of these cases, there is a common thread: chronic inflammation, mitochondrial dysfunction, and impaired tissue oxygenation at the microvascular level. HBOT—via hard or soft chambers, depending on the indication—helps address all three by improving oxygen delivery, modulating immune responses, and supporting cellular repair pathways.

What an HBOT Course May Look Like

Specific protocols vary based on the condition being treated and the type of chamber used.

For neurologic or chronic inflammatory conditions in an outpatient setting, a typical soft‑chamber course may involve:

• sessions 4-5 days per week
• each session lasting 60-90 minutes in the chamber
• a series of 20-40 sessions to start, with reassessment and potential additional blocks based on response

Some patients feel subtle changes within the first 10-15 sessions; others notice more gradual shifts over the course of a full protocol. Because HBOT works by changing cellular signaling and gene expression, benefits often accumulate over time rather than appearing all at once.

Hospital‑based hard‑chamber protocols for approved indications follow different, more intensive medical guidelines and are not interchangeable with mild protocols.

Safety and Screening

HBOT is generally well tolerated, but it is still a medical treatment and not appropriate for everyone. Common temporary side effects can include ear pressure or sinus discomfort from the change in pressure, mild fatigue after sessions, or rarely claustrophobia in the chamber. Certain conditions—like untreated pneumothorax (collapsed lung)—are contraindications, and medications or lung, ear, or seizure history need to be reviewed prior to treatment.

For this reason, therapies should be supervised, to control how quickly the pressure change occurs, monitoring for comfort, by clinicians familiar with the therapy and with your broader medical picture, ideally integrated into a full treatment plan.

The Bottom Line

If you feel stuck—fatigued, foggy, inflamed—and standard tests do not fully explain why, it may be less about permanent damage and more about cellular dysfunction, especially in how your body uses oxygen and controls inflammation. Hyperbaric Oxygen Therapy is one tool that can help shift that physiology by enhancing oxygen delivery, supporting mitochondrial function, and nudging the immune system back toward balance.

Hard chambers remain essential for serious, acute conditions, while soft chambers—especially when paired with an oxygen concentrator—offer a gentler, often safer way to bring many of these benefits into chronic‑care and wellness settings for appropriately selected patients. When combined with a comprehensive functional medicine plan, HBOT can be a powerful catalyst for healing at the cellular level.

---

References

1. Smeraglia F, et al. Hyperbaric oxygen treatment: effects on mitochondrial function. International Journal of Molecular Sciences, 2021.
   https://pmc.ncbi.nlm.nih.gov/articles/PMC8699286/
2. Hajjar W, et al. The mechanisms of action of hyperbaric oxygen in restoring host homeostasis. Frontiers in Physiology, 2023.
   https://pmc.ncbi.nlm.nih.gov/articles/PMC10452474/
3. Undersea and Hyperbaric Medical Society. Hyperbaric oxygen therapy indications and mechanisms. Accessed 2026.
   https://www.uhms.org
4. Johnson C. The HBOT hope: hyperbaric oxygen therapy for fibromyalgia, ME/CFS, and long COVID. Health Rising blog, 2022.
   https://www.healthrising.org/blog/2022/12/27/hbot-hyperbaric-oxygen-chronic-fatigue-fibromyalgia-long-covid/
5. ME Research UK. Is hyperbaric oxygen therapy effective for ME/CFS, fibromyalgia and long COVID? 2023.
   https://www.meresearch.org.uk/hyperbaric-oxygen-therapy/
6. HBOT USA. Soft vs hard hyperbaric chambers: pros and cons. 2024.
   https://hbotusa.com/soft-vs-hard-hyperbaric-chambers-pros-and-cons/
7. Peak Primal Wellness. Is 1.3 ATA enough? The science of mild hyperbaric therapy. 2026.
   https://peakprimalwellness.com/blogs/wellness/is-13-ata-enough-the-science-of-mild-hyperbaric-therapy
8. OneBase Health. Is mild hyperbaric oxygen (mHBOT) therapy effective? 2024.
   https://onebasehealth.com/blogs/education/is-mild-hyperbaric-oxygen-mhbot-therapy-effective
9. National Hyperbaric. Difference between hard and soft hyperbaric chambers. Accessed 2026.
   https://www.nationalhyperbaric.com/hyperbaric-oxygen-therapy/difference-hard-soft-hyperbaric-chambers
10. Lin H, et al. New insights of hyperbaric oxygen therapy: focus on inflammatory and immune modulation. Precision Clinical Medicine, 2024.
    https://academic.oup.com/pcm/article/7/1/pbae001/7577619
11. Chen Y, et al. Hyperbaric oxygen therapy modulates immune effector responses. Frontiers in Immunology, 2026.
    https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2026.1777972/full
12. Thom SR, et al. Hyperbaric oxygen and regenerative medicine. Integrative Cancer Therapies hyperbaric review, 2022.
    https://www.liebertpub.com/doi/10.1089/ict.2022.29033.jso
13. HBOT.com. Hyperbaric oxygen therapy’s role in stem cell mobilization and implantation. 2025.
    https://hbot.com/hyperbaric-oxygen-therapys-role-in-stem-cell-mobilization-and-implantation/
14. Loiacono A. Hyperbaric oxygen therapy and stem cells: the science of regenerative synergy. 2025.
    https://adamloiacono.com/hyperbaric-oxygen-therapy-and-stem-cells-the-science-of-regenerative-synergy/
15. Boussi‑Gross R, et al. Hyperbaric oxygen therapy can improve post concussion syndrome years after mild traumatic brain injury. PLOS ONE, 2013.
    https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0079995
16. HBOT has a better cognitive outcome than normobaric oxygen for patients with post concussion syndrome. Clinical study, 2023.
    https://pmc.ncbi.nlm.nih.gov/articles/PMC10508512/
17. Hadanny A, Efrati S, et al. Hyperbaric oxygen therapy efficacy in mild traumatic brain injury. Frontiers in Neurology, 2022.
    https://www.frontiersin.org/journals/neurology/articles/10.3389/fneur.2022.815056/full
18. Zhang Y, et al. Hyperbaric oxygen therapy improves post concussion symptoms in chronic traumatic brain injury. 2025.
    https://pmc.ncbi.nlm.nih.gov/articles/PMC12440767/
19. Ueno S, et al. Exposure to a mild hyperbaric oxygen environment elevates blood oxygenation and improves performance. Biomedical Reports, 2022.
    https://pmc.ncbi.nlm.nih.gov/articles/PMC9057685/
20. Pioneer Valley Hyperbaric. Mild vs high pressure HBOT: 1.3 ATA evidence. Accessed 2026.
    https://www.pioneervalleyhyperbaric.com/mild-vs-high-pressure-hbot-understandi
21. Macypan. Hyperbaric oxygen therapy at 1.3 atm is as effective as 100% oxygen therapy at 2.4 atm? Accessed 2026.
    https://www.macypan.com/hyperbaric-oxygen-therapy-at-13-atm-is-as-effective-as-100-oxygen-therapy-at-24-atm.html
22. Virginia Hyperbaric. Chamber differences: medical HBOT vs mild hyperbaric air therapy. 2018.
    https://virginiahyperbaric.com/chamber-differences
23. Ogasawara R, et al. Mild hyperbaric oxygen exposure enhances peripheral circulatory function and physical performance. International Journal of Environmental Research and Public Health, 2023.
    https://pmc.ncbi.nlm.nih.gov/articles/PMC9965672/
24. LPCETN. The benefits of a hard vs a soft sided hyperbaric chamber. 2024.
    https://www.lpcetn.com/blog/the-benefits-of-a-hard-vs-a-soft-sided-hyperbaric-chamber/
25. Port Chiropractic. Hyperbaric oxygen therapy at 1.3 atm at room temperature is just as effective as 100% oxygen therapy at 2.4 atm? 2020.
    https://portchiro.com/blog/article/2020/5/18/hyperbaric-oxygen-therapy-1-3-atm-room-temperature-just-effective-100-oxygen-2-4-atm
26. Rossignol DA, Rossignol LW, Smith S, et al. Hyperbaric treatment for children with autism: a multicenter, randomized, double-blind, controlled trial. BMC Pediatrics. 2009;9:21.
27. Renewal mHBOT Research. Autism: mHBOT Research & Studies (summary of HBOT trials at 1.3 ATA).
28. ASAT (Association for Science in Autism Treatment). Double-blind, controlled trial of hyperbaric treatment for children with autism (research synopsis).
29. ClinicalTrials.gov. Effects of Hyperbaric Oxygen Therapy in Autistic Children (NCT00324909).
30. Kinaci M, Kinaci A. Hypothesis for how hyperoxic therapy may facilitate effective biologic correction of autism. Journal of Integrative Neuroscience. 2020.
31. Cureus. A descriptive study on the impacts of hyperbaric oxygen therapy on autistic individuals using caregiver reports.
32. James SJ, Melnyk S, Jernigan S, et al. Evidence of oxidative damage and inflammation associated with low glutathione redox status in the autism brain. Translational Psychiatry. 2012.
33. Guo T, et al. Oxidative stress in autism spectrum disorder—current progress of mechanisms and biomarkers. International Journal of Molecular Sciences. 2022.
34. IntegrativeMedicine.ca. Glutathione and detox pathways in autism: why optimizing detoxification systems is crucial for individuals with ASD (clinical overview).
35. Patrick S, et al. The effects of hyperbaric oxygen treatment on verbal scores in individuals with autism spectrum disorder. Brain Sciences. 2024.
36. Kaur R, et al. Cellular and molecular mechanisms of SARS-CoV-2 spike proteinmediated endothelial dysfunction. 2026.
37. Pretorius E, et al. Microclots in Long COVID: Understanding their role in chronic symptoms (expert review and summary).
38. Shin J, et al. Sustained vascular inflammatory effects of SARS-CoV-2 spike protein and implications for post-acute sequelae. 2025.
39. Global Virus Network. Long COVID and the vascular endothelium (overview of endothelial injury and dysregulation). 2023.
40. Leite A, et al. Damage to endothelial barriers and its contribution to long COVID. Nature Reviews Cardiology. 2023.
41. Yale Medicine. Does hyperbaric oxygen therapy (HBOT) help treat Long COVID? 2024.
42. YourHBOT. The science behind HBOT and mitochondrial dysfunction (clinical summary of mitochondrial effects). 2025.
43. Frontiers in Immunology. Immune dysregulation and endothelial dysfunction associate with Long COVID; viral persistence as a leading theory. 2025.
44. Community Hyperbaric. Hyperbaric oxygen therapy: A promising treatment for Long COVID (clinical and mechanistic overview). 2025.
45. Efrati S, et al. Hyperbaric oxygen treatment: Effects on mitochondrial function and redox homeostasis. 2021.
46. Suzuki Y, et al. SARS-CoV-2 spike protein induces endothelial inflammation via ACE2-dependent mechanisms. Scientific Reports. 2023.
47. ESMED. Hyperbaric oxygen therapy for Long COVID: Evidence review (mechanisms and trial data). 2025.
48. Kim J, et al. Hyperbaric oxygen increases mitochondrial biogenesis and function with oxidative stress in cardiomyocytes. J Appl Physiol. 2025.
49. Ceban F, et al. Long COVID: Pathophysiological factors and abnormalities of microcirculation and endothelial inflammation. 2023.
50. Zhang Y, et al. Hyperbaric oxygen treatment for Long COVID: Mechanisms and clinical trial outcomes. 2023.
51. Jain KK. Hyperbaric oxygen therapy. In: StatPearls. 2023.
52. Thom SR. Hyperbaric oxygen therapy. J Intensive Care Med. 1998;13(3):137-148.
53. HBOT USA. How HBOT bypasses red blood cell limits (discussion of plasma-dissolved oxygen at 1.3 ATA and with supplemental oxygen).
54. MedStar Health. Hyperbaric oxygen therapy: indications, mechanisms, and safety considerations.
55. NUMA Oxygen. Hyperbaric oxygen therapy: enhancing regeneration and healthy aging (overview of soft vs hard chamber use cases).
56. Vann RD, Butler FK, Mitchell SJ, Moon RE. Hyperbaric oxygen therapy and gas effects in clinical practice (discussion of oxygen toxicity risk at various pressures).
57. Rossi M, et al. Endothelial dysfunction and cardiovascular disease: hyperbaric oxygen therapy as a potential adjunct (microcirculation and clinical indications).